Compare BioNTech SE - ADR (BNTX) vs FTAI Aviation Ltd (FTAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs FTAI Aviation Ltd — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while FTAI Aviation Ltd trades at $211.9 (market cap $21.17B). The key difference: BioNTech SE - ADR and FTAI Aviation Ltd are close in size by market cap, and FTAI Aviation Ltd pays a 0.73% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | FTAI | |
|---|---|---|
Market Cap | $22.86B | $21.17B |
Sector | Health | Industrials |
52-Week High | $119.34 | $310.04 |
52-Week Low | $83.89 | $109.92 |
Enterprise Value | $6.53B | $24.21B |
Dividend Yield | — | 0.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
FTAI Aviation trades at $209.88, down 7.68% today, amid a bearish technical signal. The stock has missed earnings estimates for three consecutive quarters, though revenue and net income remain robust. Recent news highlights strategic collaborations and growth in data center power solutions. Analyst consensus is unanimously bullish with 18 buy ratings.
The outlook is supported by strong fundamentals and growth initiatives, but risks include earnings misses and high valuation multiples. The stock's near-term performance hinges on Q2 2026 results and execution of new business segments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →
